Akero Therapeutics, Inc. (DELISTED) (AKRO:DL)

54.65 0.00 (0.00%) USD  |  NASDAQ  |  Dec 18, 16:00
More

Akero Therapeutics SG&A Expense (TTM): 43.02M for Sept. 30, 2025

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for AKRO:DL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Pfizer Inc. 13.91B
Eli Lilly & Co. 10.39B
Bristol Myers Squibb Co. 7.222B
Johnson & Johnson 23.38B
Gilead Sciences, Inc. 5.886B